A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer
NCT ID: NCT00649090
Last Updated: 2008-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1549 participants
INTERVENTIONAL
2005-03-31
2007-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exemestane group
exemestane
Exemestane 25 mg oral tablet once daily for a maximum of 3 years
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
exemestane
Exemestane 25 mg oral tablet once daily for a maximum of 3 years
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with early breast cancer after adequate loco-regional treatment and eventual adjuvant chemotherapy, treated with tamoxifen for 2-3 years OR treated with tamoxifen for 2-3 years and consecutive exemestane treatment, provided the total duration of endocrine treatment is less than 5 years
* Estrogen receptor positive breast cancer patients
* Patients who remain free from disease following treatment with tamoxifen
Exclusion Criteria
* Patients taking hormone replacement therapy
* Donation of blood or blood products for transfusion during the 30 days prior to initiation of treatment with study drug, at any time during the program or 30 days after completion of treatment
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Aalst, , Belgium
Pfizer Investigational Site
Antwerp, , Belgium
Pfizer Investigational Site
Arlon, , Belgium
Pfizer Investigational Site
Baudour, , Belgium
Pfizer Investigational Site
Bonheiden, , Belgium
Pfizer Investigational Site
Bouge, , Belgium
Pfizer Investigational Site
Boussu, , Belgium
Pfizer Investigational Site
Braine-l'Alleud, , Belgium
Pfizer Investigational Site
Brasschaat, , Belgium
Pfizer Investigational Site
Bruges, , Belgium
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Charleroi, , Belgium
Pfizer Investigational Site
Chênée, , Belgium
Pfizer Investigational Site
Chimay, , Belgium
Pfizer Investigational Site
Dendermonde, , Belgium
Pfizer Investigational Site
Duffel, , Belgium
Pfizer Investigational Site
Edegem, , Belgium
Pfizer Investigational Site
Eupen, , Belgium
Pfizer Investigational Site
Genk, , Belgium
Pfizer Investigational Site
Ghent, , Belgium
Pfizer Investigational Site
Gilly (Charleroi), , Belgium
Pfizer Investigational Site
Gosselies, , Belgium
Pfizer Investigational Site
Halle, , Belgium
Pfizer Investigational Site
Hasselt, , Belgium
Pfizer Investigational Site
Herstal, , Belgium
Pfizer Investigational Site
Hornu, , Belgium
Pfizer Investigational Site
Huy, , Belgium
Pfizer Investigational Site
Kortrijk, , Belgium
Pfizer Investigational Site
La Louvière, , Belgium
Pfizer Investigational Site
Leuven, , Belgium
Pfizer Investigational Site
Libramont, , Belgium
Pfizer Investigational Site
Lier, , Belgium
Pfizer Investigational Site
Liège, , Belgium
Pfizer Investigational Site
Mechelen, , Belgium
Pfizer Investigational Site
Merksem, , Belgium
Pfizer Investigational Site
Mons, , Belgium
Pfizer Investigational Site
Montigny-le-Tilleul, , Belgium
Pfizer Investigational Site
Mouscron, , Belgium
Pfizer Investigational Site
Namur, , Belgium
Pfizer Investigational Site
Ottignies, , Belgium
Pfizer Investigational Site
Rocourt, , Belgium
Pfizer Investigational Site
Roeselare, , Belgium
Pfizer Investigational Site
Seraing, , Belgium
Pfizer Investigational Site
Sint-Niklaas, , Belgium
Pfizer Investigational Site
Soignies, , Belgium
Pfizer Investigational Site
Tongeren, , Belgium
Pfizer Investigational Site
Torhout, , Belgium
Pfizer Investigational Site
Tournai, , Belgium
Pfizer Investigational Site
Turnhout, , Belgium
Pfizer Investigational Site
Verviers, , Belgium
Pfizer Investigational Site
Waregem, , Belgium
Pfizer Investigational Site
Wilrijk, , Belgium
Pfizer Investigational Site
Yvoir, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5991077
Identifier Type: -
Identifier Source: org_study_id